psilocin (ELE-101) / Eleusis Therap - LARVOL DELTA

Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms. (PubMed, CNS Drugs) - "Following the US Food and Drug Administration (FDA) approval of esketamine and brexanolone in 2019, industry investment in therapeutics with novel mechanisms for mood and anxiety disorders has expanded, catalyzing a new wave of innovative interventions...The drug names discussed are ALTO-100, ALTO-203, ALTO-207, ALTO-300, BHV-7000, BI-1569912, BPL-003, COMP360, DT120, ELE-101, GATE-251, GH001, GM-1020, GM-2505, HLP003, MK-1942, NBI-1065845, NBI-1070770, NV-5138, PIPE-307, SEP-363856, SPT-300, VLS-01, and XEN1101. The US Clinical Trials registry (clinicaltrials.gov), MEDLINE, conference proceedings, and company communications such as press releases were consulted to obtain up-to-date trial information and reported outcomes. Overall, the therapeutic landscape shows an expanding range of clinical compounds under active development; nonetheless, persistent challenges remain, including approaches to therapeutics where functional unblinding may occur, the ways in which to..."

Journal • P2/3 data • Review • CNS Disorders • Mood Disorders • Psychiatry

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression (clinicaltrials.gov) - P1/2 | N=84 | Active, not recruiting | Sponsor: Eleusis Therapeutics | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2025 ➔ Mar 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression (clinicaltrials.gov) - P1/2 | N=84 | Recruiting | Sponsor: Eleusis Therapeutics | Trial completion date: Sep 2024 ➔ Feb 2025 | Trial primary completion date: Apr 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression (clinicaltrials.gov) - P1/2 | N=84 | Recruiting | Sponsor: Eleusis Therapeutics | Phase classification: P2a ➔ P1/2 | Trial completion date: Dec 2023 ➔ Sep 2024 | Trial primary completion date: Dec 2023 ➔ Apr 2024

Phase classification • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression (clinicaltrials.gov) - P2a | N=84 | Recruiting | Sponsor: Eleusis Therapeutics | Trial completion date: Jul 2023 ➔ Dec 2023 | Trial primary completion date: Jul 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression (clinicaltrials.gov) - P2a | N=66 | Recruiting | Sponsor: Eleusis Therapeutics | Trial completion date: Mar 2023 ➔ Jul 2023 | Trial primary completion date: Mar 2023 ➔ Jul 2023

Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression (clinicaltrials.gov) - P2a | N=66 | Recruiting | Sponsor: Eleusis Therapeutics | Phase classification: P1 ➔ P2a

Phase classification • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

ELE-101 Safety & Tolerability Study in Healthy Participants (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Eleusis Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open

ELE-101 Safety & Tolerability Study in Healthy Participants (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Eleusis Therapeutics | Trial completion date: Nov 2022 ➔ Mar 2023 | Trial primary completion date: Nov 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date

ELE-101 Safety & Tolerability Study in Healthy Participants (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Eleusis Therapeutics

New P1 trial